3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
33
NIH
4
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Arthritis, Rheumatoid
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Graft vs Host Disease
6
Leukemia
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Lymphoma, Follicular
4
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
3
Lymphoma
3
Psoriasis
2
Neoplasms
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Accelerated Phase
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
2
Burkitt Lymphoma
2
Urinary Bladder Neoplasms
1
Stomatitis
1
Recurrence
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neutropenia
1
Mycosis Fungoides
1
Multiple Myeloma
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoproliferative Disorders
1
Interventions
Dexamethasone
307
Bortezomib
161
Lenalidomide
130
pomalidomide
112
daratumumab
94
carfilzomib
69
Calcium Dobesilate
41
Cyclophosphamide
40
belantamab mafodotin
31
elotuzumab
30
fludarabine
27
ixazomib
23
isatuximab
21
Melphalan
21
venetoclax
18
selinexor
17
talquetamab
15
Prednisone
15
plerixafor
14
Panobinostat
14
Granulocyte Colony-Stimulating Factor
14
Injections
12
idecabtagene vicleucel
11
Zoledronic Acid
11
Thalidomide
11
Azacitidine
11
pembrolizumab
10
tocilizumab
9
nirogacestat
9
liposomal doxorubicin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Multiple Myeloma
×
Methotrexate
×
Clear all
NCT04960579
2026-04-24
MM
Poseida Therapeutics, Inc.
Phase 1
Active not recruiting
275 enrolled